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The introduction of highly potent, Ttcell spetcific immunosuppressive drugs such as cytclosporine in the late 1980s revolutionized 
the practice of transplantation due to its substantial 
impact in preventing rejection episodes and enhancet
ments in both patient and allograft survival. However, 
after a while, it emerged that these agents have some 
side effects, which can adversely affect transplantation 
outcome. Deficient cytotoxic T cell function due to 
pharmacologic immunosuppression in transplantation 
settings sensitizes these patients to postttransplantat
tion malignancies including lymphoproliferative disort
ders (PTLD), which represent a heterogeneous group 
of pathologic lymphoid hyperplasia and lymphoid 
neoplasia.1,2 PTLD is a challenging complication of 
organ transplantation and is usually fatal if untreated.3 
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BACKGROUND AND OBJECTIVES: Knowledge of the significance of post-transplant lymphoproliferative disor-
ders (PtLD) that occur “very late” or more 10 years after renal transplantation is limited. thus, we analysed and 
compared characteristics and prognosis of the disease in renal transplant patients with very late onset PtLD vs. 
early- and late-onset PtLD.
DESIGN AND SETTING: retrospective study of data obtained from comprehensive search of medical literature 
PATIENTS AND METHODS: We searched for available data using the Pubmed and Google scholar search engines 
for reports of lymphoproliferative disorders occurring in renal transplant patients by disease presentation time. 
RESULTS: We analyzed data from 27 studies that included 303 patients with lymphoproliferative disorders 
after renal transplantation. renal graft recipients with very late onset PtLD were significantly less likely to be 
under mycophenolate mofetil (mmf)- and/or tacrolimus (fK-506) (vs. azathioprine) -based immunosuppres-
sion (P=.035) and less likely to have a history of antibody induction immunosuppression (P<.001). Compared 
to “early onset” disease, “very late” onset PtLD is more likely to develop in older patients (P=.032). survival 
analysis did not show any difference in outcome (P=.5). no organ involvement priority was found for this patient 
group (P>.1 for all).
CONCLUSIONS: older renal transplant patients are at increased risk for development of very late onset 
PtLD, and should be strictly followed. further multi-institutional prospective studies are needed to confirm 
our results.
Current evidence suggests that recipients of solid ort
gan allografts are at a 25t to 500tfold greater risk for 
developing PTLD with an overall reported incidence 
of about 1% to 20%.4t8 The incidence of PTLD is ret
ported to be dependent on factors, including the type 
of allograft transplanted, the immunosuppression type 
and intensity, the occurrence of viral infections, particut
larly EpsteintBarr virus (EBV), underlying disease, and 
patient age.9t16 The prevalence of PTLD in renal transt
plant recipients is the least compared with most other 
organ recipients and is about 1%,8,17 with higher rates in 
the pediatric setting,18,19 possibly due to a lower rate of 
EBV positivity before transplantation.20 
The time of the malignancy onset is one of the most 
relevant characteristics of the PTLD and can predict 
the behavior and features of the disease. Early onset 
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(occurring within the first year postttransplantation) 
and latetoccurring PTLD (developing more than one 
year after transplantation) each have distinct pathologt
ical and prognostic characteristics, and therefore may 
have different risk factors. PTLD generally manifests 
during the first postttransplantation year21t23 and can 
present from less than a month to as late as several 
decades later. Latetonset PTLD represents a distinct 
clinicopathological subset, occurring more frequently 
in older patients with a long latency period, often dist
plays EBV negativity, responds poorly to treatment and 
has a worse prognosis.24 Some investigators have introt
duced a new category for the onset time of the PTLD: 
“very late onset” disease, which indicates PTLD with 
a time interval of longer than 10 years between transt
plantation and PTLD appearance. Due to the very 
limited number of  “very late onset” PTLD diagnosed 
in the individual and multicenter transplantation dat
tabases, current knowledge of the significance of this 
new category is limited. In our previous studies, we 
studied early and late onset PTLD in renal and liver 
transplant recipients.15,25,26 The present study, however, 
aims to clarify specific aspects of PTLD, including its 
histopathological and clinical features, predictors and 
prognosis, when it occurs beyond the tenth year postt
transplantation. The study includes the largest number 
of renal transplant recipients whose data have been 
analyzed and reported in the current literature.
PATIENTS AND METHODS
We conducted a comprehensive search for available data 
using the Pubmed and Google scholar search engines 
for reports of lymphoproliferative disorders occurring 
in renal transplant patients with regard to the disease 
presentation time. Keywords were “lymphoproliferative 
disorders + transplantation + renal + late onset” “lymt
phoproliferative disorders + transplantation + kidney 
+ very late onset” “lymphoproliferative disorders + renal 
transplantation + presentation time” “lymphoproliferat
tive disorder + renal transplantation + time to PTLD” 
“PTLD + renal + late onset” “PTLD + renal + very late 
onset” “lymphoproliferative disorders + renal transplant
tation + onset”. When we were not able to achieve the 
full text of an article, emails were sent to correspondent 
authors requesting the article. Then we only included 
studies in which data for each patient was presented 
separately. To minimize selection bias, we only included 
studies reporting a series of patients from single or mult
ticenter populations. Studies with any specific selection 
criterion were excluded from the analysis; moreover, 
only studies that had patients in the “very late” group 
and at least one of the remaining two groups (earlyt and 
latetonset) were included in this analysis. A standard 
questionnaire was developed to collect data from differt
ent published studies. Finally, data from 27 previously 
published studies from various countries5,27t52 were int
cluded in the study. The time between transplantation 
and PTLD onset was defined as the period between the 
graft and the first signs of PTLD or diagnosis, based 
on each study’s approach. Patients who presented with 
PTLD within the first 12 months postttransplantation 
were considered the “earlytonset PTLD” group; renal 
recipients presenting with the disease beyond this time 
but less than 10 years after transplantation were categot
rized as “late onset” PTLD patients. “Very late onset” 
PTLD was diagnosed when it occured after the tenth 
year post transplantation.
Because data from the studies varied in methodolt
ogy, we were not able to get all the data we needed for 
all patients. Disseminated lymphoma was diagnosed 
when the authors stated it was present or when at 
least three different organs (different lymph node areas 
were excluded from analysis due to lack of knowledge 
on how to categorize) were involved in PTLD, which 
was reported in 27 (17.4%) patients (151 patients had 
missing data). Multiorgan involvement was defined as 
involvement of more than a one organ as well as more 
than one lymphatic region, which was available in 62 
(32.8%) patients (117 had missing data). 
At the time of lymphoma diagnosis, all patients were 
receiving or had received immunosuppressive regimens 
consisting of varying combinations of azathioprine, 
prednisone, cyclosporine, mycophenolate mofetil, and 
antithymocyte/lymphocyte globulin (ATG/ALG) and 
OKT3. More or less, a rather uniform approach was 
used to manage all PTLD patients in the included ret
ports. On diagnosis of PTLD, the first step in almost 
all reports was to decrease or discontinue immunosupt
pressive therapy; different regimens of chemotherapy 
with or without surgical interventions were also used 
for some of patients. 
Response to treatment was defined as any favorable 
change in the cancer measures as well as patient clinical 
condition. Data on response to treatment was reported 
by authors for only 148 (48.4%) patients of whom 98 
(66.2%) patients responded to anticancer treatment. 
However, we developed new criteria for defining ret
mission rates for the study population. A remission 
episode was defined when patients were alive at their 
24th month since PTLD diagnosis (since all reported 
cases meeting this criterion had at least one confirmed 
remission episode) and no remission was defined when 
a patient died within the first month posttPTLD diagt
nosis (because among reported cases there were no pat
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tients who died at the first postttransplant month and 
none reported any remission episode). For patients who 
died between these two time periods, no modification 
was made. According to this criteria, 213 (69.6%) had 
data on remission of whom 77 (36.2%) had at least one 
response to treatment, irrespective of their future dist
ease course. Overall mortality was 154 patients (50.8% 
of the study population and 55.4% of the reported 
cases; 25 had missing data); death due to PTLD was 
defined when if authors stated it or when the patient 
died within 6tmonths postdiagnosis, or when patients 
died due to PTLD treatment complications. Overall 
101 patients (37.7% of the reported data; 65.6% of the 
whole mortality rate) died due to the disease based on 
the abovementioned criteria. 
Software used for data analyses was SPSS v.13.0. 
Statistical differences between subgroups were pert
formed by using χ2 and Fisher exact tests for prot
portions and the t test for continuous data. Onetway 
ANOVA was used for comparing continuous data bet
tween the three patient groups. The Bonferroni test was 
used for multiple comparisons. Survival analysis was 
done with life tables and KaplantMeier methods and 
the logtrank test. All statistical tests were performed at 
the P=.05 significance level.
RESULTS
Data on 303 patients who developed lymphoproliferat
tive disorders after renal transplantation were included 
in the analysis. EBV infection was documented in 176 
(57.5%) patients, of whom 121 (68.8%) were reported 
positive. There were 171 (62%) males and 105 (38%) 
females (30 patients had missing data). Mean (SD) age 
at diagnosis of PTLD was 43.1 (16.9) years. The mean 
(SD) interval between transplantation and the diagnot
sis of PTLD was 77 (67.3) months whereas followtup 
time after diagnosis of PTLD was 23.7 (30.7) months. 
Renal graft recipients with very late onset PTLD 
were significantly less likely to be under mycophenot
late mofetil (MMF) and/or tacrolimus (FKt506) (vs. 
azathioprine)tbased immunosuppression (P=.035) 
and less likely to have a history of antibody induction 
immunosuppression (P<.001) (Table 1). Renal transt
plant recipients with very late onset PTLD had other 
characteristics comparable to their counterparts with 
late onset disease. No priority for organ involvement 
was found for very late onset PTLD compared to other 
patients (Table 2). Age at the time of transplantation 
was not different when the very late group was comt
pared to others together, but a post hoc analysis of the 
three patient groups showed that the “very late” onset 
PTLD was more likely to develop in older patients 
(P=.032). 
At the last follow, 154 (50.8%) patients were dead 
(25 had missing data). When death for any reason was 
used as the final outcome, the logtrank test did not 
show any difference between the two groups in survival 
(P=.497; Figure 1); moreover, no statistically signifit
cant difference was seen between the two groups when 
death due only to PTLD was used as he final outcome 
(based on the defined criteria in the methods section; 
P=.266). A separate reanalysis of the data when all the 
three patient groups were entered into analysis did not 
change the results (P=.714; Figure 2). One and fivet
year survival rates for the very late onset PTLD patients 
were 56% and 29%, respectively; compared to 62% and 
35%, respectively, for the controls.
DISCUSSION
After the recent improvements in the production and 
use of highly potent immunosuppressants, a substantial 
improvement has been observed in the overall survival 
of patients who receive organ grafts, including renal 
transplants. This trend of longer survival time as well as 
the special impact of the newly introduced immunosupt
pressive agents has increased the possibility of very late 
occurrence of PTLD.53,54 
Lymphomas are more likely to develop among graft 
recipients within the first 12 months postttransplant
tation, which is usually termed as earlytonset PTLD, 
but the incidence rate has declined over the years; this 
fact, along with the substantially higher rate of mort
tality in the early period postttransplantation leaves 
a limited number of PTLD cases occurring after the 
tenth postttransplant year. Therefore, we compared our 
results with studies reporting both late onset and very 
late onset PTLD. In our series, 23% (71 patients) were 
in the “very late” onset PTLD group and the remaining 
patients developed the disease before the tenth postt
transplant year. Nevertheless, we were not able to draw 
a firm conclusion on the incidence of the very late onset 
PTLD after renal transplantation through this study, 
because of the methodological limitations, including 
the need to exclude some studies from the analysis and 
because the reported data does not represent the whole 
or even a comparable sample of the PTLD patients (i.e., 
it does not include data from all centers of the world). 
An EBV positive serology might be associated with 
the time of PTLD appearance with a significant trend 
toward a longer time between transplantation and 
PTLD for EBVtnegative patients (reviewed by Thomas 
Lowe et al 55 and Daniela Capello et al 56). In this study 
of 303 patients, we detected a significantly lower rate 
of EBV infection for the very late onset PTLD comt
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pared to early onset disease; although the difference was 
not significant when early and late onset PTLD were 
pooled and compared with the very late PTLD.  
Potent immunosuppressive agents have been associt
ated with an earlier development of lymphomas postt
transplantation. A major study from the Collaborative 
Transplant Study database reported that treatment 
with antibody induction therapy increases the risk of 
lymphoma only during the first year after transplantat
tion, whereas the risk was similar to that in nontantit
bodyttreated patients in subsequent years.57 In the curt
rent study, we found that patients under more potent 
immunosuppressants (MMF and/or FKt506) were sigt
nificantly more likely to develop early PTLD while azat
thioprinetbased therapy was more frequently observed 
in the very late onset PTLD. Moreover, use of antibody 
Table 1. Characteristics of renal transplant recipients with early and late onset PTLD.
Variables 
Time to PTLD P (two-sided) Available 
data (number 
of patients)
Early onset 
(n=52)
Late onset 
(n=180)
Very late 
onset (n=71)
Very late vs. 
others
Three groups 
comparison
Mean (SD) age (years) 37.6 (18.3) 43.6 (16.4) 46 (17) .119 .032 286
Pediatric (%) 7 (15.2) 13 (8) 5 (8.3) 1.0 .314 269
Gender male (%) 22 (52.4) 102 (61.4) 45 (69.2) .189 .211 273
Time to PTLD 
development (months) 6.2 (3.5) 59.7 (30.9) 172.7 (57.5) - - -
Time from diagnosis to 
death (monoths; dead 
patients included only)
31.6 (6.9) 16.3 (1.8) 12.4 (2.2) .67 .203 139
Multiorgan involvement 
(%)a 11 (31.4) 38 (31.7) 13 (31) 1.0 .996 197
Disseminated PTLD (%)a 8 (26.7) 13 (13.4) 6 (15.4) 1.0 .224 166
Immunosuppression 
(azathioprine-based) 
(%)b 
21 (53.8) 75 (67.6) 28 (82.4) .044 .035 184
Cell types (% B cell) 22 (88) 57 (70.4) 22 (68.8) .505 .179 138
Morphology .650 .249 162
   Early lesion
   (plasmacytic 
   hyperplasia)
0 6 (6.3) 2 (5.4)
   Polymorphic B cell  
   lymphoma 12 (41.4) 21 (21.9) 6 (16.2)
   Monomorphic PTLD 14 (43.8) 61 (63.5) 25 (67.6)
   Hodgkin lymphoma 3 (10.3) 8 (8.3) 4 (10.8)
EBV status (%) 20 (90.2) 72 (67.3) 27 (61.4) .259 .044 173
Mortality rate (%) 25 (54.3) 95 (56.9) 34 (52.3) .572 .810 278
Remission episode (%)c 16 (58.6) 60 (65.2) 21 (77.8) .184 .301 148
Remission episode (%)a 22 (61.1) 86 (64.7) 28 (63.6) 1.0 .925 213
Monoclonal lesions vs. 
polyclonal (%) 5 (41.7) 24 (77.4) 8 (100) .088 .010 51
Lymphoma cell type B 
cell (%) 22 (88) 57 (70.4) 22 (68.8) .179 138
Use of induction therapy 
(%) 19 (61.3) 62 (66) 9 (26.5) <.001 <.001 159
aAccording to the criteria defined in the methods section; bversus under MMF and/or FK-506-based immunosuppression; cauthor reported.
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Table 2. Frequency of involved organs in 168 renal transplant recipients with early or late onset PTLD.
Involved 
organs 
Time to PTLD P Available data 
(number of 
patients)Early onset Late onset Very late onset 
Very late vs. 
others
Between three 
groups
Skin 3 (8.6) 36  (27.5) 14 (26.9) .711 .060 218
Stomach 0 5 (4.5) 2 (4.7) .662 .446 187
Genitalia 0 2 (1.8) 0 1.0 .493 187
CNS  14 (33.3) 22 (17.9) 10 (20.8) 1.0 .109 213
Spleen 0 5 (4.5) 2 (4.5) .665 .415 189
Colon 1 (2.9) 3 (2.7) 1 (2.3) 1.0 .985 187
Small intestine 1 (2.9) 17 (15.2) 5 (11.6) 1.0 .160 189
Renal 
involvement 9 (26.5) 13 (11.6) 4 (9.3) .453 .05 189
Liver 
involvement 2 (5.9) 14 (12.5) 3 (7) .572 .397 189
Respiratory 
system 11 (39.3) 14 (15.4) 8 (21.6) 1.0 .025 156
Heart 2 (9.5) 2 (2.5) 0 .424 .306 133
Bone marrow 2 (5.9) 6 (5.5) 11 (5.9) .717 .937 187
induction in the very late onset disease was significantly 
less common than that in the other two groups.
Evidence suggests that very late onset PTLD is more 
frequently of the monoclonal type while early onset 
disease is mostly polymorphic. Webber et al58 have ret
ported that almost threetquarters of patients developt
ing PTLD less than 3 years from transplantation were 
polymorphic in nature, while more than half of the late 
onset cases were monomorphic. Moreover, earlytonset 
PTLDs, occurring within 1 year after transplantation, 
are supposed to be mainly polyclonal; however, most 
latetonset PTLDs are monoclonal lymphoid malignant
cies (reviewed by Daniela Capello et al56). In the curt
rent study, although very late onset PTLD had a trend 
toward monomorphic lesions, it did not reach statistical 
significance. Nevertheless, PTLD lesions in all of the 
reported cases in the very late onset group were monot
clonal and the difference was significantly higher than 
those in the other two groups. 
Based on the current literature, latetonset PTLD 
more frequently represents extratgraft localization and 
widespread disease with involvement of multiple nodal 
and extranodal sites.17,56 Moreover, a lesser incidence of 
graft involvement in the latetonset PTLD has been ret
ported compared to that in the earlytonset PTLD.59t61 
However, in the current study, we found no difference 
between the groups with regard to multiorgan involvet
ment and disseminated disease. On the other hand, 
the rate of renal allograft involvement was significantly 
lower in the patients developing very late onset PTLD. 
In our previous reports on allograft localization of 
the PTLD in renal, liver and lung transplantation, we 
showed that PTLD presenting in the graft are signifit
cantly more likely to develop within the first year after 
transplantation.9,15 About half of the heart allograft 
PTLD cases were also in the early onset PTLD group, 
although statistical significance was not achieved (unt
published data). 
Wasson et al speculated that PTLD occurring in 
late postttransplantation might be associated with poor 
survival.37 The evidence suggests a higher rate of mortalt
ity among latetonset than that in earlytonset PTLD;17 
Armitage et al described their observation that an int
creased duration of immunosuppression contributes 
to a more severe and possibly advanced clonal evolut
tion.62 Moreover, it is reported that late onset PTLD 
less frequently responds to treatment.63 However, in the 
current study of international data, we found no surt
vival difference between different PTLD groups based 
on presentation time, and survival curves were fairly 
similar. This finding raises doubts on current speculat
tion over the prognosis of late onset PTLD. Our study 
population with very late onset PTLD were under imt
munosuppression over 10 years, but had survival rates 
comparable with early and late onset PTLD.
Potential criticisms of our study are that the study 
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Figure 1. Survival curves of renal transplant recipients 
developing “very late” PTLD versus other onset times (P=.497).
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Figure 2. Survival curves with all three patient groups (P=.714).
population was gathered from different reports with int
consistent approaches. We believe that this is the major 
limitation for this study, leading to substantial missing 
data for some of study variables and thus, decreasing 
the power of our analyses. This limitation was most 
prominent for special data that are not typically includt
ed in reports on PTLD patients. Another limitation is 
that the results of different studies were not presented 
in the same way. For example, the report of response 
to treatment was presented very dissimilarly: as partial 
or complete remission in one, while only “response to 
treatment” in another. Better methods are needed to act
cumulate the existing data for analysis. 
In conclusion, we found that renal transplant pat
tients who develop PTLD in the very late postttranst
plantation period have comparable patient outcomes to 
those with earlier onset disease. They also had similar 
rates of multiorgan involvement and disseminated dist
ease. On the other hand, very late onset PTLD was ast
sociated with monoclonal lesions and use of less potent 
immunosuppressants. Further multitinstitutional prot
spective studies are needed to confirm our results.
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